Clinical trial · Observational
Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection
Relationship of Polymorphisms and Mutations of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitors Responsiveness in Non-small-cell Lung Cancer Patients
NCT00831454CI-TRIAL-00016175completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study was to retrospectively evaluate associations between EGFR and AKT DNA-polymorphisms involved in transcriptional regulation and overall survival in NSCLC patients treated with EGFR-TKIs.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| NON-SMALL-CELL LUNG CANCER | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- to evaluate the presence of EGFR- and AKT-DNA polymorphisms.
- timeFrame
- At the end of enrollment
Secondary outcomes (1)
- measure
- to correlate the biological characteristics with clinical characteristics and survival data of patients.
- timeFrame
- At the end of enrollment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Availability of tumor tissue or blood samples. * Diagnosis of NSCLC * At least one treatment with EGFR-TKIs inhibitors Exclusion Criteria: * Other than NSCLC primary diagnosis * No treatment with EGFR-TKIs inhibitors * No archival tissue available
References
Publications (0)
Data not yet available
No reference posted for this study.